Medical Project

CURRICULUM VITAE

Name: JIANYU RAO, M.D., F.C.A.P.

Date of Birth: February 16, 1964

Current Title/Office Address:

Professor of Pathology and Epidemiology

Director of Cytopathology

Director of Cytopathology Fellowship Program

Director of Gynecological Pathology

Department of Pathology & Laboratory Medicine

UCLA Medical Center

10833 Le Conte Avenue

Los Angeles, CA 90095, U.S.A

Tel: 310-***-**** fax: 310-***-****

Pager: 1-800-***-****, ext. 15090

Email: abqins@r.postjobfree.com

Education:

Fellow:

07/98 to 06/99 Cytopathology, Department of Pathology, University of California at Los Angeles, Los Angeles, CA

Residency:

07/94 to 06/98 Anatomical and Clinical Pathology, Department of Pathology, University of California at Los Angeles, Los Angeles, CA

Postdoctoral:

03/87 to 09/92 Research Fellow, Chemoprevention and Biomarker, Department of Urology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma, OK

Medical School:

09/79 to 07/84 Shanghai Medical University, Shanghai, People’s Republic of China

Licensure:

Medical License, The Medical Board of California

Board Certification:

AP/CP, The American Board of Pathology - 1998

Cytopathology, The American Board of Pathology - 2002

Certified by CYTYC for Thinprep GYN slide examination - 2000

Certified for urine ImmunoCyt analysis - 2005

Professional Experience:

Full Professor (tenured), Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, and Department of Epidemiology, School of Public Health, University of California at Los Angeles (UCLA), Los Angeles, CA, 07/09

Associate Professor (tenured), Step 3, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, and Department of Epidemiology, School of Public Health, University of California at Los Angeles (UCLA), Los Angeles, CA, 07/03 to 07/09

Director, Cytopathology Division, Department of Pathology and Laboratory Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, 07/08 to present

Director, Gynecological Pathology, Department of Pathology and Laboratory Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, 02/07 to present

Director, Cytopathology Fellowship Program, Department of Pathology and Laboratory Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, 07/03 to present

Faculty, Greater Los Angeles Cytotechnology Training Consortium, 07/99 to present

Assistant Professor, Department of Pathology and Laboratory Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, 07/99 to 06/03

Director of Cytopathology Research, Department of Pathology and Laboratory Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, 06/99 to present

Attending Physician, UCLA Medical Center and Santa Monica Hospital, Los Angeles, CA, 07/99 to present

Clinical Sciences Adjunct Faculty, California State University at Dominguez Hills, Carson, CA10/00 to present

Assistant Researcher, Department of Pathology, UCLA, Los Angeles, CA, 01/95 to 06/99

Research Assistant Professor, Department of Urology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 09/92 to 07/94

Research Investigator, Department of Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Beijing, P. R. China, 07/84 to 03/87

Professional Activities:

Clinical Activities:

Subspecialty sign out for GU and GYN pathology and cytopathology

Perform Fine Needle Aspiration

Participate in weekly tumor board for Genitourinary Tract and Gynecological cancers

Medical legal review for cytology (Pap smears) and gynecological tumors

Professional Associations and Scholarly Societies:

Member, California Nano-System Institute (CNSI), 2008-now

Member, American Society of Cytopathology, 2007-present

Member, The International Society of Urological Pathology, 2005-present

Member, International Gynecologic Cancer Society, 2005-present

Member, Gerson Lerman Group Healthcare Council, 2003-present

Member, The International Society for Preventive Oncology, 1996-present

Member, Sigma-Xi Scientific Society, Oklahoma Chapter, 1993-1994

Member, American Society of Clinical Pathologists, 1995-present

Fellow, College of American Pathologists, 1999-present

Member, American Association for Cancer Research, 1999-present

Member, American Association for the Advancement of Science, 2000-present

Member, American Medical Association, 1994-1999

Member, People to People Ambassador Program, Cytopathology Delegation to China. Organized by International Academy of Cytopathology, 1997.

Consulting Activities:

05/92 to 06/94 Scientific Consultant, Cytodiagnostic Inc. (UroCo), Oklahoma City, OK

11/01 to 02/02 Scientific Consultant, Superarray Inc., Rockefeller, MD

08/01 to 09/02 Co-founder and Scientific Consultant, StemCyte Inc., Pasadena, CA

05/02 to present Guest Professor, Nanjing Medical University, NanJing, China

07/02 to present Visiting Professor, Fujian Medical University, Fujou, China

12/05 to present Scientific Advisory Board, Journal of Longevity

01/06 and 12/06 Scientific Advisory Board, DiagnoCure Inc.

03/06 to present Consultant, Windyhills Med Inc.

06/06 Scientific Advisory Board, AVIVA, San Diego, CA

03/29/07 AMA’s academic Physician Focus Group discussion, Los Angeles

07/01/08 Co-founder and scientific advisory board member, Edeixa, LLC

06/01/09 Consultant, Primegen Biotech LLC

Grant Review Committees:

06/97 & 06/98 Study Section for Carcinogenesis, Nutrition, and Prevention, American Cancer Society.

10/01 09/08 Study Section for Ovarian Cancer, Department of Defense

05/02 & 09/04 Cancer Research UK

04, 05 &07 FAMRI (Flight Attendant Medical Research Institute)

03/05, 01/07 Susan Love Research Foundation

06/06, 02/07, 02/08, 02/09 Ad-hoc member, Epic study section, NCI, NIH

09/06 Fondation contre le Cancer, fondation d'utilit publique

02/07 VA Clinical-Trial Development Award

12/07 to present Pennsylvania Department of Health Final Performance Review

07/09 to 06/13 Member, Epic cancer study section, NCI, NIH

Journal Services:

Managing Editor: Frontiers in Bioscience.

Editor: International J of Biomedical Sciences

Editorial Board member: Recent Patent on Anti-Cancer Drug Discovery

The Open Cancer Journal

Reviewer: Journal of Urology, International Journal of Cancer, Cancer Detection and Prevention

Ad hoc reviewer: Nature Biotechnology, Frontiers in Bioscience, Biomed Central, Journal of Clinical Oncology, Journal of Cellular Biochemistry, Cancer Investigation, International Journal of Gynecological Cancer, Cancer Detection and Prevention, Recent Patent on Anti-Cancer Drug Discovery, Analytical and Quantitative Cytology and Histology, Breast Cancer Research, Pancreas, Check Samples, American Journal of Pathology

Honors and Special Awards (Selected):

Provost’s Research Fellowship Award, 1987-89, University of Oklahoma Health Sciences Center.

Young Investigator Award of Seventh Annual Meeting of Clinical Applications of Cytometry, 1992, $1,000.

Richard F. Dwyer and Elaine W. Dwyer Award for Excellence from the Jonsson Comprehensive Cancer Foundation, 1996, $5,000.

Finalist for ASCP/CAP Pathology Resident Award Competition, Spring Meeting, 1998.

First award, LASOP Pathology Research Competition, 1999.

Who’s Who in America (Marquis), 2000-2001.

International Health Professional of the Year 2003 (International Biographical Centre)

International Scientist of the Year 2003 (International Biographical Centre)

International Health Professional of the Year 2006 (International Biographical Centre)

2007 USCAP Annual Meeting received Stowell - Orbison Certificate of Merit award for resident research project entitled "Prostate Stem Cell Antigen as an Adjunctive Marker for Urothelial Carcinoma in Urine Cytology Specimens"

Teaching:

10/04 – present University of California, Los Angeles, School of Public Health, Lecture in Cancer Epidemiology "Tumor Pathology for Epidemiologist"

00/01 - Present University of California, Los Angeles, School of Public Health, Lecture in Molecular Epidemiology of Cancer

"Molecular Biology in Epidemiology"

10/98 - Present University of California, Los Angeles, School of Cytotechnology, Lecture in New technology in urine cytology", "HPV and cervical smears", and "Image analysis versus flow Cytometry"

10/98 - Present University of California, Los Angeles, School of Public Health, Lecture in Cancer Epidemiology "Tumor Biomarkers and Cancer Prevention"

10/98 – Present University of California, Los Angeles, David Geffen School of Medicine, Medical Student Classes for Gynecological and Genitourinary Tract Pathology and Cytopathology

10/98 - Present University of California, Los Angeles, Department of Pathology and Lab Med, Lecture in Tumor Marker and Cancer Prevention"

Aug 16-20, 2004 Summer Course: Molecular Epidemiology of Cancer, Instituto Nacional De Salud Publica, Guanavaca, Mexico, August 16-20.

Research Grants

CURRENT

P.I., Rao J. 08/01/09-07/31/13 5%

(Main PI: Poola, I. Howard University)

R01CA142646 NCI/NIH $250,000

Multicenter Validation of Breast Cancer Risk Prediction Markers

The goal of this project is to validate an identified marker profile for the predication of invasive breast cancer in patients who has been diagnosed with Atypical Ductal Hyperplasia.

P.I., Rao J. 08/01/09-11/31/11 10%

R01CA133066 NCI/NIH $320,000

Genetic alterations, genome instability and progression of PCa

The goal of this project is to study genetic alterations and changes of different stages of prostate cancer progression using genome-wide association approach

P.I., Rao J. 04/01/09-03/30/10 5%

Calvis Pharm $108,000

hENT1 study for AML and pancreatic cancers

The goal of this project is to test hENT1 as a therapeutic predicative marker for AML and pancreatic cancer patients

P.I., Rao J. 11/01/07-12/31/09 10%

AVON $130,487

The Development of a Breast Fluid Test to Identify Women at Risk for Breast

Cancer

This project aims to develop a dip-stick based test for breast cancer risk assessment.

Co-P.I., (Susan Love) 07/01/07-06/30/09 10%

CBCRP $97,480

Effect of Intraductal Therapy of DCIS with Pegylated Liposomal Doxorubicin on Pathology and Biomarkers: A Presurgery Study

This project aims to test the concept of intraductal therapy in detecting and treating DCIS of breast.

P.I., Rao J. 07/07 – 10/09 2%

Gene-Probe Inc. $39,000

"APTIMA HPV Research Assay Evaluation"

This project aims to validate the new HPV detection method.

Co-P.I., (Lu, Q) 07/07-06/09 2%

R03-CA12859 NCI/NIH $100,000

"Green Tea Targets COX-2/PGE2 and EFGR Pathways in NSCLC via Stimulating

Annexin 1"

COMPLETED (selected)

Co-P.I.,(Zhang ZF) 01/01/08-12/30/08 2%

Jonsson Comprehensive Cancer Center $50,000

DNA Repair Genes in Prediction of Risk, Therapeutic Response and Prognosis of Bladder Cancer"

The goal of this project is to identify genetic susceptibility markers for bladder cancer risk prediction for individuals without cancer in order to prevent bladder cancer development and to discover genetic markers to predict therapeutic response and clinical prognosis for patients with bladder cancer.

P.I., Rao J. 07/06-07/07 10%

Journal of Longevity $70,000

Nutritional intervention for chronic diseases

This project will test the effects of various nutritional compounds on inflammation and proliferation in vitro.

Co-Investigator (Mao J.) 04/01/03-03/31/08 5%

U01 CA96134/NCI $100,000 (total 5,000,000)

Chemoprevention of Lung Cancer

The goal of this project is to test the chemopreventive effect of COX-2 inhibitor for lung cancer.

P.I., Rao J 06/01/05-05/30/07

Jonsson Comprehensive Cancer Center $35,000

Actin Remodeling in Bladder Cancer

The goal of this project is to study gene-environmental interaction in bladder cancer carcinogenesis and actin remodeling pathways.

P.I., Rao J 08/01/03-07/31/06 10%

Biomarker Core, $732,125 (total $4,902,594)

in Chemoprevention of Superficial Bladder Cancer, main P.I. Belldegrun A U01CA96116/NCI

This project will test the chemopreventive effect of Green Tea extract and EP.I.,dermal Growth Factor Receptor (EGFR) inhibitor Iressa on newly diagnosed superficial bladder cancers. As a Core Leader for the Biomarker Core of this project, Dr. Rao's laboratory will be responsible for the development and evaluation of the intermediate end point markers for the chemoprevention trial.

P.I., Rao J 09/01/04-08/30/05 5%

California Breast Cancer Research Program $100,000

10-DB-0158

Surrogate Markers for Green Tea

The goal of this project is to perform a P.I.,lot study to test the effect of green tea on breast cancer chemoprevention using biomarkers bFGF as surrogate markers.

P.I., Rao J. 09/01/95 - 06/31/01 50%

R29CA71080 NCI $ 345,981

Actin as a Marker for Bladder Cancer Prevention and Management.

The goal of this project was to investigate molecular mechanisms of cytoskeletal actin alteration in bladder cancer carcinogenic process, and whether such alterations can be utilized as a marker for bladder cancer detection.

P.I., Rao J. 07/01/01-06/30/02 5%

DAMA17-01-1-0495 Department of Army $75,196

Biomarker Analysis of Ductal Lavage Fluid As a Tool for Breast Cancer Early Detection

The goal of this project was to carry out a P.I.,lot study to determine whether specific molecular changes in ductal eP.I.,thelial cells obtained by breast ductal canalization can be used as intermediate end point markers for breast cancer early detection.

P.I., Rao J. 04/01/03-02/31/04 5%

NCI/NIH $31,000

An ID-Tag Protein Profiling Array for the Molecular Characterization of Cancer, SBIR (Subcontract with Superarray Inc.)

The goal of this project is to develop and test a novel technology for molecular analysis of cancer cells.

P.I., Rao J. 04/01/03-03/31/04 5%

Susan Love Foundation $20,000

Intraductal Approach for Breast Cancer Monitoring in Contralateral Breast

The goal of this study is to test the ductal lavage as a tool for breast cancer monitoring in contralateral breast.

P.I., Rao J. 10/01/03-10/30/05

Ventana Medical Inc. $5,000

HPV in situ testing on cervical cytological and tissue materials

The goal of this project is to determine whether HPV testing on cervical biopsy and cytology samples can be a marker for cervical premalignant lesions.

Co-Investigator (Zhang Z) 04/01/02-03/31/05 5%

R21 ES 011667/NIH/NIEHS $150,000

Molecular EP.I.,demiology and Gene-Environment Interaction

This is a planning grant for molecular eP.I.,demiology in Environmental genome. The award will be used to establish a molecular eP.I.,demiology research program focusing on environmental genome.

Co-Investigator (Zhang Z) 04/01/01-03/31/06 5%

P50 CA90833/NCI $264,095

Lung Cancer SPORE Project 1: Molecular EP.I.,demiology of Lung Cancer.

This is a population-based case-control study with 600 cases with lung cancer and 600 controls from Los Angeles. Blood samples, buccal cells, and tumor tissues will be collected and a panel of selected genetic molecular alterations will be measures. Possible gene-environment interaction will be evaluated

Other project involvement:

Diagnocure Inc/ Comparative study of UroVysion and ImmunoCyt /J. Rao, 5%, 11/06- 12/06, $32,500

Faculty Member/ P.I. R Bastani & P Ganz, Cancer Control Post-Doctoral Training Grant

P.I., Rao J., Clin.Nutr. Cen./ In vitro Study of the Chemopreventive Effect of G. Lucidum for Bladder Cancer 2002-2003, Direct Cost $20,000

P.I., Rao J., S Love Found./ Molecular field mapP.I.,ng study of breast ducts, 2001-2002, Direct Cost $10,000

P.I., Duvall K., JCCC/ Biomarkers in breast fluid in high risk women, 2001-2002, Direct Cost $30,000

P.I., Willy D., CRC/ P.I.,lot Study of the Relationship between HAART and Anal Cellular AtyP.I.,a in HIV Infected Cohort of Men who Have Sex with Men, 2001-2002, Direct Cost $35,000

P.I., Hemstreet G., NCI (1R01-OH02647)/ Biological Monitoring/Risk Assessment in an Exposed Cohort in China, 1992-1997, Direct Cost $1,059,886

P.I., Li J., NCI (N01-CN-65000)/ Sino-USA Collaborative P.I.,lot Study of Lung Cancer Intervention Trial Among Yunnan Tin Miners, 1985-1987, Direct Cost $30,000

P.I., Li J., NCI (N01-CP-71118)/ A Historical Cohort Study of Employees of Yunnan Tin Corporation and A Case-Control Study of Lung Cancer in Gejiu City, a part of Sino-USA Collaborative EP.I.,demiology Studies of Cancer in China, 1985-1988, Direct Cost $75,000

Faculty Member/PI, Zhang ZF, Molecular Epidemiology Training Grant

Pathologist/PI, Chia D, Cancer Biomarker Validation Center Grant, Early Detection Research Network (EDRN), NCI/NIH

Pathologist/PI, Chia D, Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial, NCI/NIH

PENDING

P.I. Rao J. 04/01/09-03/31/14 25%

R01CA-138760 NCI/NIH $1,925,000

Cell Nanomechanics in Cancer Molecular Epidemiology

The goal of this research is to develop atomic force microscope as a new tool for cancer diagnostics.

Invited Lecture and Presentations: (Selected):Actin as a Risk Factor and Modulable Endpoint for Cancer Chemoprevention Trials. Third International Symposium, Impact of Cancer Biotechnology on Diagnostic and Prognostic Indicators in Predictive Oncology and Therapy, The International Society of Preventive Oncology, Nice, France, Oct 26-28, 1996.

Quantitative Fluorescence Image Analysis in Cytology. People to People Mission Symposium – New Technologies in Cytology. International Society of Cytopathology, in Cancer Institute, Chinese Academy of Medical Sciences, Beijing Feb 1997.

Cytoskelatal actin as a morphological effector for apoptosis. ASCP/CAP Spring Meeting, 1998.

Multiple biomarker analysis in archival Fine Needle Aspiration specimens using the novel Quantitative Fluorescence Image Analysis. 46th Annual Scientific Meeting, American Society of Cytopathology, Nashville, TN, 1998.

Biomarkers and molecular pathology of bladder cancer progression. Ground Rounds, Department of Pathology and Lab Medicine, UCLA, Jan 1999.

Molecular pathology of early bladder neoplasm. Seminar, Department of Pathology, University of Pennsylvania Medical Center, Jan 1999.

Biomarkers of bladder cancer progression. Ground Rounds, Department of Pathology and Lab Medicine, University of Iowa Medical Center, Feb 1999.

Transitional cell carcinoma of bladder – the current status of molecular pathology. Seminar, Department of Pathology and Lab Medicine, University of California at Irvine, Feb 1999.

Molecular pathology and biomarkers of early bladder lesions. Ground Rounds, Department of Pathology and Lab Medicine, M.D. Anderson Cancer Center, 1999.

Development of biomarkers for fine needle aspiration evaluation of breast cancer. Los Angeles Society of Pathology, May 1999.

QFIA analysis of biomarkers to detect bladder cancer in an occupational cohort. Seminar, Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China, Sept 1999.

A novel approach for multiple biomarker analysis in archival breast fine needle aspiration. Keystone Symposium, Cancer Molecular Epidemiology, Taos, NM, Mar 2000.

Molecular pathology and biomarkers of early bladder lesions. Ground Rounds, Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China, April 2000.

Alteration of cytoskeletal actin during malignant transformation and apoptotic process, Part I. Seminar, Ovarian Cancer Research Group, JCCC, Mar 2000.

Alteration of cytoskeletal actin during malignant transformation and apoptotic process, Part II. Seminar, Ovarian Cancer Research Group, JCCC, May 2000.

Molecular biology in epidemiology. Lecture, Department of Epidemiology, School of Public Health, UCLA, May 2000.

Cytoskeletal actin network as a novel target for cancer chemoprevention and therapy. Lecture, The Fourth Life Spring Symposium, Beijing, China, August 2000.

Cytokeratin 20 as a simple early detection marker for transitional cell carcinoma (TCC) in archived urine slides. Oral Presentation. The 5the International Symposium on Predictive Oncology & Therapy - Impact of Biotechnology on Cancer Diagnostic & Prognostic Indicators. Geneva, Switzerland October 28-31, 2000.

Actin polymerization agent Jasplakinolide induces cell cycle perturbation and delayed apoptosis in the cytotoxic agent resistant K562 cells. Oral Presentation. The 5the International Symposium on Predictive Oncology & Therapy - Impact of Biotechnology on Cancer Diagnostic & Prognostic Indicators. Geneva, Switzerland, October 28-31, 2000.

Molecular Targeting of Cytoskeleton Actin Network as a Novel Chemotherapeutic and Chemopreventive Approach. Molecular Biology and New Therapeutic Strategies: Cancer Research in the 21st Century. Maui, Hawaii, February 12-16, 2001.

Cervical Cancer and Pap Smear: Past, Present, and Future. Henry Ford Medical Center Grand Round, March, 2001

Breast Cancer Tumor Markers: Perspective and Our Approach. The 2nd Symposium on Breast Cancer Standard Therapy and Management - Recent Developments. Invited Speaker, Cancer Hospital/Institute, Chinese Academy of Medical Sciences, Beijing, China, May 10, 2001.

Uniform Approach for Fine Needle Aspiration Diagnosis of Breast Lesions. Invited Speaker, Cancer Hospital/Institute, Chinese Academy of Medical Sciences, Beijing, China, May 25, 2001.

Molecular Field Mapping Study of Breast Ducts. The 2nd Symposium on The Intraductal Approach to Breast Cancer, The Susan Love MD Breast Cancer Foundation, Santa Barbara, Jun 3, 2001.

Urine Cytology and Tumor Markers for Bladder Cancer Cancer Hospital/Institute, Chinese Academy of Medical Sciences, Beijing, China, Aug 17, 2001.

Intermediate End Point Markers for Chemoprevention Studies - Bladder Cancer as a Model. Cancer Chemoprevention and Molecular Epidemiology Symposium, Jonsson Comprehensive Cancer Center, Oct. 2, 2001.

Experiences in Medical School Teaching and Practice Medicine in both China and U.S. Symposium on Contemporary Medical Education. Tsinghua Medical University. Oct. 24, 2001.

Actin Remodeling Profile in Cancer Management and Prevention. Berlex Biosciences, Nov. 14, 2001.

29. Molecular Biology in Epidemiology. Nanjing Medical University, Nanjing, China. March 14, 2002.

30. Biomarkers for Cancer Chemoprevention Trials. Nanjing Medical University, Nanjing, China. March 14, 2002.

31. Biology, Molecular Epidemiology, Biomarkers and Chemoprevention for Bladder Cancer. Nanjing Medical University, Nanjing, China. March 15, 2002.

32. Updates in the Diagnosis and Management of Bladder Cancer. Shanghai RenJi Hospital, Shanghai Second Medical University, Shanghai, China. March 18, 2002.

33. Intermediate End Point Markers in Bladder Cancer Chemoprevention. Seminars in Epidemiological Research Mini Symposium: Molecular Epidemiology in Chemoprevention Palm Spring, June 21, 2002.

Biomarker and Chemoprevention of Bladder Cancer. Eastern China 4th Epidemiological Congress, Shanghai, China. June 24, 2002.

Tumor Cell Enrichment in Body Fluid - Bladder Cancer as an Example. AVIVA Bioscience Inc., San Diego, CA. Sept 23, 2002.

Molecular Field Mapping and Ductal Lavage as a Tool for Breast Cancer Risk Assessment in Chinese Women. 3rd International Santa Barbara Symposium: The Intraductal Approach to Breast Cancer, Santa Barbara, CA, March 27-30, 2003.

37. Intraductal Approach for Risk Monitoring in Contralateral Breast in Women with Breast Cancer in China. 3rd International Santa Barbara Symposium: The Intraductal Approach to Breast Cancer, Santa Barbara, CA, March 27-30, 2003.

Biomarkers for Cancer Chemoprevention Trials. Mini-Symposium: Molecular Markers in Cancer Risk Assessment and Detection (Prostate/Breast/Bladder). Sponsored by the Department of Surgery, Section of Urologic Surgery and Eppley Institute, University of Nebraska Medical Center, August 12, 2003.

FNA combined with Flow Cytometry for the initial evaluation of lymphoadenopathy. The 1st Beijing-International Leukemia/Lymphoma Workshop: Updates from Diagnosis to Therapy, UCLA-United Family Hospital and Beijing University, Beijing, China, April 15, 2004.

Cervical Cancer and Pap Smear: Past, Present, and Future. Workshop for Liquid Based Cytology, GuanZhou People’s Hospital, April 19, 2004.

Cervical cancer and Pap Smear: UCLA Experience. 8th National Conference on Gynecological Oncology. Shanghai, China. April 24, 2004.Molecular Biology in Epidemiology. Summer Course: Molecular Epidemiology of Cancer, Instituto Nacional De Salud Publica, Guanavaca, Mexico, August 16-20, 2004.

Intermediate Markers for Chemoprevention. Summer Course: Molecular Epidemiology of Cancer, Instituto Nacional De Salud Publica, Guanavaca, Mexico, August 16-20, 2004.

The Application of Biomarkers. Summer Course: Molecular Epidemiology of Cancer, Instituto Nacional De Salud Publica, Guanavaca, Mexico, August 16-20, 2004.

Biomarkers for Cancer Chemoprevention Trials. Asian-Pacific Conference of Tumor biology and Medicine, 2004, 21st IATMO Conference, Xian, China. August 21-25, 2004.

Chair person, Symposium D. Asian-Pacific Conference of Tumor biology and Medicine, 2004, 21st IATMO Conference, Xian, China. August 21-25, 2004.

47. Cervical cancer and Pap smear. Continuing Medical Education Symposium on Cervical Cancer and Precancerous Lesions, Cancer Centre, Sun Yat-Sen University, GuanZhou, China. September 7-11, 2004.

48. Fine Needle Aspiration cytology of pancreatic lesion: the present and the future. 4th National Conference on Pancreatic Cancer. Nanchang, China. September 9, 2004.

49. Cytoskeletal actin remodeling – A potential target for cancer therapy and prevention. World Conference on Magic Bullets, Nurnberg, Germany, Sept 11, 2004.

50. Cellular biomarkers for ductal lavage samples. 4th International Symposium on the Intraductal Approach to Breast Cancer in Santa Barbara. March 10-13, 2005.

51. Biomarker study of green tea-based chemoprevention trials of bladder cancer. JCCC Molecular Epidemiology Symposium: Advances of Gene-Environmental Interaction and Cancer Risk. UCLA. April 15, 2005.

52. Biomarkers for chemoprevention Trials. City of Hope. Los Angeles, CA. May 20, 2005.

53. CSF cytology. The 2nd Clinical Exfoliate Cytology Symposium. Guangdong Provincial People’s Hospital. Guangzhou, China, June 1-4, 2005.

54. Urine Cytology. The 2nd Clinical Exfoliate Cytology Symposium. Guangdong Provincial People’s Hospital. Guangzhou, China, June 1-4, 2005.

55. Bladder Urothelial Neoplasm: From Histology to Cytology. Kaiser, Panorama City, Los Angeles, CA. July 12, 2005.

56. Cervical cancer and Pap smear: Past, Present, and Future. Continuing Medical Education Symposium on Gynecological Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. August 9-12, 2005.

57. Cervical cancer screening. Symposium on Cervical Cancer Screening, Jiames Women’s and Children’s Hospital, China. August 27, 2005.

58. Latest in Fecal Occult Blood Testing for Colon Cancer Screen. GI and Liver Symposium . Asian American Medical Association. Los Angeles, CA. October 9, 2005.

Genetic Susceptibility and lung cancer among non-smokers. Tobacco-Related Research Program Conference. Los Angeles, CA. October 10, 2005.

60. Urine cytology: from morphology to biomarkers. Teleconference Network of

Texas. October 25, 2005.

Contact this candidate